Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 295-301

  Kangarloo, S Bill ^a   Naveed, Farrukh ^a   Ng, Ella S M ^a   Chaudhry, M Ahsan ^a   Wu, Judy ^a   Bahlis, Nizar J ^a   Brown, Christopher B ^a   Daly, Andrew ^a   Duggan, Peter ^a   Geddes, Michelle ^a   Quinlan, Diana ^a   Savoie, Mary Lynn ^a   Shafey, Mona ^a   Stewart, Douglas A ^a   Storek, Jan ^a   Yang, Maggie ^a   Zacarias, Nancy ^a   Yue, Ping ^a   Magliocco, Anthony M ^a   Russell, James A ^a  

^a FOOTHILLS HOSPITAL   (Canada)

Author keywords

Busulfan; Infusion rate; Test dose

Indexed keywords

BUSULFAN; FLUDARABINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION RATE; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; AGED; BUSULFAN; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYELOABLATIVE AGONISTS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855596926     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.015     Document Type: Article

References (25)

1. Russell J.A., Kangarloo S.B. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008, 14:1936-1949.
2. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
3. Andersson B.S., Gajewski J., Donato M., et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000, 25(Suppl 2):S35-S38.
4. Andersson B.S., Kashyap A., Couriel D., et al. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant 2003, 9:722-724.
5. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002, 8:145-154.
6. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
7. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
8. Bartelink I.H., Bredius R.G., Ververs T.T., et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:88-98.
9. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
10. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493-500.
11. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
12. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
13. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
14. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
15. Pidala J., Kim J., Anasetti C., et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010, 3:36-44.
16. Tse W.T., Duerst R., Schneiderman J., Chaudhury S., Jacobsohn D., Kletzel M. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant 2009, 44:145-156.
17. Beri R., Chunduri S., Sweiss K., et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010, 45:249-253.
18. Rowland M, Tozer TN, Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 4th ed. Baltimore: Wolters Kluwer/Lippincott Williams & Wilkins; 2011, p. 52.
19. Gibaldi M, Perrier D, Pharmacokinetics, 2nd ed. Revised and Expanded. New York: Marcel Dekker, Inc.; 1982:27-28.
20. Eberly A.L., Anderson G.D., Bubalo J.S., McCune J.S. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008, 28:1502-1510.
21. Hassan M., Oberg G., Bjorkholm M., Wallin I., Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993, 33:181-186.
22. Hassan M., Oberg G., Ehrsson H., Ehrnebo M., et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989, 36:525-530.
23. Johnson-Davis K.L., McMillin G.A., Juenke J.M., Ford C.D., Petersen F.B. Which dose of busulfan is best?. Clin Chem 2010, 56:1061-1064.
24. Lewis V., Naveed F., Kangarloo S.B., et al. Influence of busulfan exposure on allogeneic transplant outcome using a fludarabine/busulfan/Thymoglobulin/total body irradiation preparative regimen for adult acute myelogenous leukemia. Bone Marrow Transplant 2010, 45(Suppl 2):S83.
25. Chan K.W., Mullen C.A., Worth L.L., et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002, 29:963-965.